Answers are grounded in this paper and cite their sources.
Systemic autoinflammatory diseases result from pathogenic variants in genes governing innate and cell-intrinsic immune pathways, leading to dysregulated sterile or overexuberant inflammation. The field has expanded rapidly from a handful of hereditary fever syndromes to a diverse spectrum of conditions that are far more common than previously imagined. Key pathways found to be recurrently involved include the inflammasome, tumor necrosis factor (TNF)/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and type I interferon signaling pathways. Mechanistic dissection of these disorders has driven the development of targeted therapies, including interleukin 1, TNF, and Janus kinase inhibitors. Such drugs have transformed patient outcomes for these genetic disorders and related common inflammatory conditions. This review examines the molecular pathophysiology, genetic paradigms, and emerging therapeutic strategies across the major categories of systemic autoinflammatory diseases.
No takes yet. Share an insight, caveat, or question.
Schnappauf et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: